Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies

Natalia Sisca Wijaya, Sidharta Salim

Abstract


In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) started in Wuhan, China, and has since become a global threat to human health. To dates, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. Several types of drug as well as vaccination are still under investigation and clinical trials worldwide. Recently, a study demonstrated ~5000-fold reduction in SARS-CoV-2 virus at 48h in cell culture after a single treatment of ivermectin. A clinical study at University of Utah found that the administration of ivermectin during COVID-19 illness in hospitalized patients is associated with lower mortality and hospital length of stay. We report three confirmed cases of COVID-19 infection with significant improvement clinically and radiologically following treatment with single dose of ivermectin.

Pada Desember 2019, wabah yang disebabkan oleh varian baru coronavirus (SARS-CoV-2) dimulai di Wuhan, China, dan saat ini telah menjadi ancaman global bagi kesehatan manusia.Hingga saat ini, respon dunia terhadap wabah COVID-19 masih terbatas pada pemantauan dan isolasi. Di seluruh dunia, beberapa jenis obat dan juga vaksinasi masih menjalani tahap investigasi dan uji klinis. Baru-baru ini, sebuah studi mendemonstrasikan bahwa satu dosis ivermectin mampu mengurangi ~5000-kali kadar SARS-CoV-2 virus dalam 48 jam pada kultur sel. Sebuah uji klinis di Universitas di Utah juga membuktikan bahwa ivermectin terbukti menurunkan angka mortalitas dan juga lama perawatan pasien COVID-19 rawat inap. Kami melaporkan tiga pasien dengan konfirmasi positif COVID-19 yang menunjukkan kemajuan signifikan klinis dan radiologis setelah pengobatan dengan satu dosis ivermectin.


References


Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; DOI:10.1056/NEJMoa2002032.

Cally L, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-COV-2 in vitro. Science Direct 2020; DOI:10.1016/j.antiviral.2020.104787.

Patel AN, Desai SSGrainger DW. et al. Usefulness of Ivermectin in COVID-19 illness. SSRN [Internet]. 2020 [cited 2020 May 8]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524

Jaroslaw D, Gorovits N. COVID-19 Alert. DLA Piper [Internet]. 2020 [cited 2020 May 8]. Available from: https://www.dlapiper.com/en/us/insights/publications/2020/04/therapies-for-covid19-what-is-in-the-pipeline/

Lundberg et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis virus replication. Antivir. Res2013;100(3):662-72.

Õmura S, Crump A: The life and times of ivermectin - a success story. Nat Rev Microbiol. 2004, 2:984-9. 10.1038/nrmicro1048

Guzzo CA, Furtek CI, Porras AG, et al.: Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002, 42:1122-33. 10.1177/009127002401382731


Refbacks

  • There are currently no refbacks.